Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Compass Therapeutics (CMPX) EBIAT (2023 - 2026)

Compass Therapeutics' EBIAT history spans 4 years, with the latest figure at -$18.3 million for Q1 2026.

  • On a quarterly basis, EBIAT fell 10.12% to -$18.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$68.2 million, a 23.45% decrease, with the full-year FY2025 number at -$66.5 million, down 34.66% from a year prior.
  • EBIAT hit -$18.3 million in Q1 2026 for Compass Therapeutics, down from -$15.7 million in the prior quarter.
  • Over the last five years, EBIAT for CMPX hit a ceiling of -$7.8 million in Q1 2023 and a floor of -$19.9 million in Q2 2025.
  • Historically, EBIAT has averaged -$13.6 million across 4 years, with a median of -$13.4 million in 2023.
  • The widest YoY moves for EBIAT: up 4.54% in 2025, down 54.19% in 2025.
  • Tracing CMPX's EBIAT over 4 years: stood at -$13.4 million in 2023, then decreased by 12.06% to -$15.0 million in 2024, then decreased by 4.54% to -$15.7 million in 2025, then decreased by 16.55% to -$18.3 million in 2026.
  • Business Quant data shows EBIAT for CMPX at -$18.3 million in Q1 2026, -$15.7 million in Q4 2025, and -$14.3 million in Q3 2025.